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Abstract
Background: Affective and psychotic disorders are mental or behavioural patterns resulting in an inability to cope
with life’s ordinary demands and routines. These conditions can be a prodromal event of Alzheimer’s disease (AD).
The prevalence of underlying AD lesions in psychiatric diseases is unknown, and it would be helpful to determine them
in patients. AD cerebrospinal fluid (CSF) biomarkers (amyloid β, tau and phosphorylated tau) have high diagnostic
accuracy, both for AD with dementia and to predict incipient AD (mild cognitive impairment due to AD), and they are
sometimes used to discriminate psychiatric diseases from AD. Our objective in the present study was to evaluate the
clinical utility of CSF biomarkers in a group of patients with psychiatric disease as the main diagnosis.
Methods: In a multicentre prospective study, clinicians filled out an anonymous questionnaire about all of their
patients who had undergone CSF biomarker evaluation. Before and after CSF biomarker results were obtained,
clinicians provided a diagnosis with their level of confidence and information about the treatment. We included
patients with a psychiatric disorder as the initial diagnosis. In a second part of the study conducted retrospectively in a
followed subgroup, clinicians detailed the psychiatric history and we classified patients into three categories:
(1) psychiatric symptoms associated with AD, (2) dual diagnosis and (3) cognitive decline not linked to a
neurodegenerative disorder.
Results: Of 957 patients, 69 had an initial diagnosis of a psychiatric disorder. Among these 69 patients, 14 (20.2 %)
had a CSF AD profile, 5 (7.2 %) presented with an intermediate CSF profile and 50 (72.4 %) had a non-AD CSF profile.
Ultimately, 13 (18.8 %) patients were diagnosed with AD. We show that in the AD group psychiatric symptoms
occurred later and the delay between the first psychiatric symptoms and the cognitive decline was shorter.
Conclusions: This study revealed that about 20 % of patients with a primary psychiatric disorder diagnosis
before undergoing a CSF exploration for cognitive disorder displayed a CSF biomarker AD profile. In memory
clinics, it seems important to consider AD as a possible diagnosis before finalizing a diagnosis of a psychiatric
disorder.
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Background
An association between Alzheimer’s disease (AD) and
thymic or psychotic disorders has been reported, sug-
gesting that they could be considered either as a risk
factor for [1, 2] or as a prodromal condition of AD [3],
or sometimes in a differential diagnosis [4, 5]. Until re-
cently, the diagnosis of AD was based on the McKhann’s
criteria [6] in clinical practice, in recent cohorts [7] and in
international clinical trials [8, 9]. However, in neuropatho-
logical studies [10, 11], positron emission tomography
(PET) amyloid imaging [9, 12] and cerebrospinal fluid
(CSF) biomarker studies, researchers have found that atyp-
ical AD forms are more frequently observed [13, 14], and
the diagnosis appears to be a challenge when it is based
only on presenting clinical features without specific bio-
markers [15, 16]. Taking into account these findings, new
criteria were proposed for AD [15], mild cognitive impair-
ment (MCI) [3] and pre-clinical stage [17], including
imaging and/or biological markers. AD CSF biomarkers
are the only markers that reflect the AD neuropathological
lesions associating tau and amyloid β [11, 18–20]. Positive
CSF biomarkers imply that patients have AD brain lesions
with or without clinically detectable AD features. These
CSF biomarkers are widely used and validated in AD in
clinical research [21, 22] and in clinical practice [23].
Importantly, these markers are normal in several other
disorders, such as depression. However, no study to
date has explored the usefulness of CSF biomarkers in
patients diagnosed with psychiatric disorders and cog-
nitive symptoms in daily clinical practice. In this large,
multicentre, prospective observational cohort study, our
aims were (1) to determine, in this subgroup with an initial
diagnosis of a psychiatric disorder, the proportion of pa-
tients diagnosed with psychiatric disorders who had CSF
AD profiles; and (2) to analyse the impact of CSF bio-
marker results on the final diagnosis in this subgroup.
Methods
Study subjects
This study was designed to investigate the impact of CSF
biomarker results on the diagnoses made by experienced
clinicians in their routine daily practice. The clinicians’ par-
ticipation was voluntary. All senior clinicians who wanted
to participate replied to an email invitation. When a clin-
ician considered a patient eligible for CSF biomarkers, he
filled out a questionnaire about the patient, for whom col-
lected information was anonymous. This questionnaire was
created by a team that included neurologists and biologists,
and then it was evaluated in clinical practice during a
1-month period by clinicians.
All recruiting centres are either secondary or tertiary
memory centres. These centres have used the same
clinical and biochemical procedures and internationally
validated criteria for the diagnosis of AD [6] and all
other forms of dementia. Patients underwent a thor-
ough examination, including clinical, neurological and
neuropsychological evaluations and brain imaging. As
recommended by the Haute Autorité de Santé (French
Health Authority), CSF biomarkers can be used in clinical
practice in cases of atypical clinical presentation and/or
rapidly progressive cognitive decline, and/or in cases of
diagnostic uncertainty, particularly in young patients.
Consequently, in France, CSF AD biomarkers are used
in clinical practice mainly in tertiary memory centres to
which patients with depression or psychiatric disorders
are also referred to determine a possible AD diagnosis.
The questionnaire was divided into two parts:
1. The first part was completed by ticking boxes before
the lumbar puncture (LP) was performed. Clinicians
were asked to mention the other explorations
performed before LP, and they were required to
indicate their most suspected diagnosis (initial
diagnosis). Clinicians were asked to rate the level of
confidence of their initial diagnosis on a numerical
visual scale ranging from 0 to 10. Diagnosis
hypotheses were established by the clinician in
charge of the patient.
2. The second part was filled out after LP and CSF
biomarker results were obtained. Clinicians were
required to indicate AD CSF biomarkers results as
“biological AD profile” or “not indicative of AD
biological profile” or “non-contributory” (including
CSF with technical problems, intermediate CSF or
CSF without interpretation). Clinicians were asked
to write their final diagnosis according to a list of
diseases and to rate their level of confidence with a
similar numerical visual scale and to indicate
possible changes concerning the medications [16].
CSF biomarker tests were performed in local laborator-
ies for all subjects. All biochemical teams were involved in
two national cohorts and shared the same standards for
CSF analysis and interpretation [24–28]. In addition, the
laboratories performed two external quality controls: one
run by a working group of the Société Française de Biolo-
gie Clinique (French Society of Clinical Biology) and the
other by the Alzheimer’s Association [29]. Our aim was to
get the most reliable and realistic opinions of clinicians in
routine clinical practice without interfering with their
diagnosis process or with their conclusions regarding the
interpretation of CSF AD biomarkers.
For the present study, we explored the subgroup with
an initial diagnosis of a psychiatric disorder before CSF
biomarker results were obtained. This subgroup was
designated as the study population. The final diagnosis
corresponded to the clinician’s final conclusion indicated
on the questionnaire at the end of all explorations. We
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considered that there was a “changed diagnosis” each
time the initial and final diagnoses were different. As
recommended in France, all diagnoses were made by a
multidisciplinary team of the research memory centres.
When possible, the psychiatric history and the precise
psychiatric diagnosis were retrospectively collected at
the end of the study from local psychiatrists and classi-
fied according to the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, Text Revision.
Retrospectively, to complete analyses, clinicians were
asked to answer the following questions for each patient:
(1) regarding the onset of the psychiatric symptoms,
new onset of psychiatric symptoms or a long history of
psychiatric symptoms; (2) age at the onset of psychiatric
symptoms; (3) information about the cognitive profile
(amnestic, dysexecutive syndrome, language disturbance,
apraxia, global dysfunction); and (4) the evolution of the
patient’s cognitive profile (improvement, stable, declining).
Finally, according to clinical information, we classified
each patient into one of three categories: (1) psychiatric
symptoms associated with AD, (2) cognitive impairment
not linked to neurodegenerative disorder or (3) dual diag-
nosis (patient with a primary psychiatric disease who then
subsequently developed neurodegenerative disease).
To evaluate the external validity of our work, we com-
pared our study population with the population registered
in the Banque Nationale Alzheimer (BNA) during the
same period "(DGOS : Direction Générale de l'Offre de
Soins) Centre Hospitaleir Universitaire de Nice". The BNA
records each consultation performed in all memory clinics
in France [30]. We considered that there was a changed
diagnosis in the BNA each time the initial diagnosis was
modified during follow-up.
Statistical analysis
Baseline characteristics of our study population were
presented and compared with our overall population
and with the BNA population (including overall popula-
tion and the psychiatric disorders subgroup). We com-
pared our overall and study populations with the BNA
population to determine if our populations were repre-
sentative of the national population of patients.
Concerning CSF biomarkers results, as CSF AD bio-
markers reflect neuropathological AD lesions, we classi-
fied patients in the biological AD category whenever the
AD CSF box was checked and in the non-AD category
when the AD CSF box was not checked. For the analysis
concerning the final diagnosis, patients were classified as
AD or non-AD. These groups were compared using χ2
statistics for categorical variables and the t test (parametric
or non-parametric) for age.
Further analyses were performed with retrospective
complementary data about the history of the psychiatric
disorder, the age of onset and the delay between the first
psychiatric symptom and cognitive decline. Because of
the lack of statistical power, the cognitive profile and the
evolution were described but not compared. Analyses
were performed using SAS 9.2 software (SAS Institute,
Cary, NC, USA).
Results
For the last two years of the present study we recorded the
results of 1015 questionnaires about patients who under-
went LP for cognitive disorders at 29 memory clinics
(including 61 senior neurologists, 65 senior geriatricians
and 2 senior psychiatrists). Fifty-eight questionnaires
(5.7 %) were excluded for missing data. A total of 957 ques-
tionnaires were ultimately analysed and were defined as
the overall population. In this overall population, 69
(7.3 %) patients were diagnosed with psychiatric disorders
as their main initial diagnosis (anxiety and/or depression
62.3 %, bipolar disorder 17.4 %, psychosis 14.5 %, others
5.8 %). This subgroup was defined as our study population.
A flowchart of the study population is presented in Fig. 1.
Characteristics of the overall population compared with
BNA (overall and patients with psychiatric disorders) are
shown in Table 1. The proportion of psychiatric disorders
was comparable in our overall and BNA populations (p =
0.29). Populations were different in terms of age but not
sex distribution; there was a female predominance. Com-
parably to our overall population, most of the patients of
the study population (n = 65, 92.9 %) were evaluated with
other examinations before undergoing LP (p = 0.27).
In comparison with our overall population, the study
population was younger (p = 0.0018) and significantly
less often diagnosed with AD (p = 0.009), but the rates of
changed diagnosis were comparable (Table 1). In com-
parison with the psychiatric BNA population (including
patients with and without CSF biomarkers), our study
population was significantly younger (p < 0.0001), more
frequently diagnosed with AD (p < 0.0001) and had a
higher rate of changed diagnosis (p < 0.0001).
Figure 1 details the repartition of CSF biomarker re-
sults and final diagnoses. According to the final diagno-
ses, patients of the study population were classified as
having AD (n = 13, 18.8 %), MCI (n = 2, 2.9 %), psychi-
atric disorder (n = 50, 79.7 %), frontotemporal dementia
(FTD) (n = 3, 4.3 %) and other neurodegenerative disease
(n = 1, 1.4 %). Subjects with a final diagnosis of AD were
not different in terms of age and sex from non-AD pa-
tients. In most cases (n = 50, 72.4 %), CSF results were
concordant with the initial diagnosis, with no changed
diagnosis. Changed diagnosis after CSF biomarker results
occurred when CSF biomarker results were discordant with
the initial diagnosis. Clinicians changed their diagnoses for
all patients who had CSF AD profiles (n = 12 for AD, n = 2
for MCI) and for two patients with intermediate biological
profiles. Among the five patients with intermediate profiles,
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we found the following diagnoses: AD (n = 1), other degen-
erative disorder without precision (n = 1) and initial psychi-
atric diagnosis (n = 3). There were 3 changed diagnoses
among the 50 patients with non-AD CSF profiles; these 3
patients were diagnosed with FTD. Finally, clinicians
concluded on a non-AD diagnosis in 100 % of cases when
CSF biomarker results were not in favour of AD.
According to the numerical scale of confidence, the
mean value for clinician certainty of the final diagnosis
was significantly increased by the use of CSF biomarkers:
8.07 ± 1.37 after CSF results versus 6.04 ± 1.41 before
(p < 0.0001). These results were comparable to those for
our overall population. The mean confidence was similar
for AD and non-AD patients (p = 0.35). Concerning the
treatment, in the study population, 24 (30.4 %) patients
had a modification of the treatment, including prescrip-
tion or stopping acetylcholinesterase inhibitors (n = 7 and
n = 5, respectively) or other modifications (n = 12).
As explained in the Methods section above, we could
determine the precise chronological link between cogni-
tive decline, psychiatric symptoms and evolution of the
disease in 41 patients. According to the clinical information
Fig. 1 Flowchart of the operational mode for patient inclusion. AD Alzheimer’s disease, CSF cerebrospinal fluid, FTD frontotemporal dementia,
MCI mild cognitive impairment
Table 1 Characteristics of the study population before cerebrospinal fluid biomarker diagnosis
Study population BNA population BNA/study population
comparison
Overall Psychiatric disorder p Value Overall Psychiatric disorder p value p Value
Number of patients 1015 69 (6.79) 317,515 24,561 (7.74) 0.29
Age, years, mean (SD) 69.2 (10.03) 64.57 (11.57) 0.0018 76.86 (12.18) 71.43 (13.82) <0.0001 <0.0001
Female sex, n (%) 504 (49.7) 43 (61.4) 0.056 199,085 (62.7) 17,661 (71.91) <0.0001 0.46
Final diagnosis of AD, n (%) 395 (38.9) 13 (18.8) 0.009 70,651 (22.25) 536 (2.18) <0.0001 <0.0001




Changed treatment, n (%) 437 (43.1) 24 (34.8) 0.13
AD Alzheimer’s disease, BNA Banque Nationale Alzheimer
Paquet et al. Alzheimer's Research & Therapy  (2016) 8:27 Page 4 of 8
we gathered, we classified patients into three categories: (1)
8 patients with psychiatric symptoms associated with AD,
among whom 7 had a CSF biomarker AD profile and 1 had
an intermediate profile; (2) 29 with cognitive impairment
not linked to a neurodegenerative disorder, including
27 with non-AD CSF biomarker profiles and 2 with
intermediate profiles; and (3) 4 with a dual diagnosis
(association of a psychiatric disease and a neurodegen-
erative disorder), including 3 with CSF AD profiles and
1 with a non-AD profile. The analysis showed that the
first psychiatric symptoms occurred significantly later
in life in the AD group than in the group with cognitive
impairment not linked to a neurodegenerative disorder
(p = 0.0002) and the group with a dual diagnosis (p =
0.004). The delay between the first psychiatric symptoms
and the onset of the cognitive decline was shorter in the
AD group than in the group with cognitive impairment not
linked to a neurodegenerative disorder (p = 0.0064) and
the group categorized with a dual diagnosis (p = 0.002).
No difference was observed between the last two cat-
egories. The results of all of these comparisons are shown
in Fig. 2.
Most of the patients in the AD group (seven of eight)
and in the dual diagnosis group (three of four) had a
cognitive decline predominantly due to amnestic impair-
ment. We found 12 patients with amnestic decline in
the group of patients with cognitive decline not linked
to neurodegenerative disorder. The predominant cogni-
tive profile in this last group was dysexecutive syndrome
(n = 17). After 3 years of follow-up, seven patients in the
AD group were in cognitive decline and one was still
stable. In the dual diagnosis group, one patient was
stable and three were in decline. In the group of patients
with cognitive decline not linked to neurodegenerative
disorder, the evolution was variable: 15 were stable, 2 were
fluctuant, 2 were improved and 5 had gotten worse.
Discussion
In this large multicentre prospective study reflecting daily
practice, we determined the biological AD profiles of pa-
tients with a primary psychiatric diagnosis. We present
the potential impact of this diagnosis on the therapeutic
management of this population. Moreover, we highlight
the differences in the age of onset and the delay between
the first psychiatric symptom and the age of cognitive
decline between patients with AD, those with a dual
diagnosis and those with cognitive decline not linked to
a neurodegenerative disorder.
The design of this prospective study was based on
consecutive inclusion and local clinical diagnosis and
biochemical examination interpretation, which made it
possible for us to make a realistic estimation of the links
between CSF biomarker results and the clinical diagnosis
of patients with psychiatric symptoms. In our overall
population, comparably to our BNA population, the per-
centage of psychiatric diagnosis was low (7.3 %), but the
proportion of patients with probable AD in this group
was notable (about 20 %). The impact of CSF biomarker
results was clear with regard to the magnitude of changed
diagnoses, with treatment modification in more than 30 %
of cases. In addition, a significant improvement in clini-
cians’ confidence in their diagnoses was noted. These re-
sults illustrate the benefit of CSF biomarker assessment
for patients with psychiatric and cognitive symptoms.
Concerning age, we noted an age difference between
our overall population, whereas there was no difference
Fig. 2 Comparison of the three categories of patients in the study: (1) psychiatric symptoms associated with Alzheimer’s disease (AD),
(2) cognitive impairment not linked to neurodegenerative disease (No Neurodeg) and (3) dual diagnosis (patient with a primary psychiatric
disease who subsequently developed AD) (dual). a Differences in age of onset of psychiatric symptoms between the three categories.
b Differences in delay between the first psychiatric symptoms and cognitive decline in the three categories ***: p<0.001
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between AD and non-AD within the study group. These
observations could be linked with the fact that early AD
can be associated with psychiatric symptoms. These re-
sults emphasize that, in memory centres, the diagnosis
cannot be based only on indications given by the patient’s
age and that often a precise history of the psychiatric
symptoms and further explorations is needed. Neverthe-
less, our study does not provide information establishing a
direct pathophysiological link between AD and psychiatric
symptoms; thus, we could not confirm that psychiatric
symptoms reveal AD pathology. We also found age differ-
ences between our populations and the BNA populations,
possibly due to the fact that BNA records all patients from
all French memory clinics [31], while our study was carried
out on a voluntary basis, and consequently we included a
limited number of centres that perform CSF biomarker
evaluations. Our overall population and our study popula-
tions were significantly younger and more frequently diag-
nosed with AD than the BNA overall and psychiatric
populations [16]. This difference is in accordance with the
recommendations by French authorities and with the
current use of CSF biomarkers that are used mainly in
younger patients or in patients with atypical presenta-
tions [23]. Furthermore, CSF AD biomarkers are more
discriminant in younger than in older patients with AD
reinforcing the tendency to assess younger individuals
[32]. Our population had a significantly higher rate of
patients with AD than the BNA population, probably
because CSF biomarker evaluations are performed when a
neurodegenerative disease is strongly suspected. In the
BNA population, all patients are recorded, including pa-
tients without any biomarkers.
Our CSF biomarker results are in accord with those in
the study by Blennow et al., who showed that in patients
with pure psychiatric disorders, the CSF biological profile
is in favour of neither AD nor an intermediate profile,
which makes the results very informative in differentiating
AD from non-AD patients [33]. Surprisingly, although
pure depression revealing dementia with Lewy bodies
(DLB) has been described previously [34], we did not find
any patients with DLB. This result could be explained by
the small cohort, the translational methodology with a
short follow-up in the retrospective part of the study, the
lack of neuropathological confirmation, and possibly mis-
diagnoses. We do know that DLB is underdiagnosed, since
only 32 % of the patients are diagnosed [35] and DLB is
frequently confused with AD or psychiatric diseases. How-
ever, patients with DLB display some specific behavioural
disorders, such as feeling of presence, illusions or vis-
ual hallucinations [36], that were not described in our
population.
In the complementary analysis, we made some very inter-
esting observations. In the AD group, the first psychiatric
symptoms occurred later in life than in the non-AD group,
confirming that new onset of psychiatric symptoms later in
life may be more suggestive of neurodegeneration. In the
AD group, the delay between the first psychiatric symptoms
and cognitive decline was relatively short (<5 years), while
it is very heterogeneous in the two other categories. We
could hypothesise that, in the AD group, the psychiatric
symptoms could be among the first symptoms of AD
linked to the regional AD lesions. In contrast, in the other
groups, the cognitive decline was associated either with
neurodegeneration or with pure psychiatric disease or a
chronic neuronal dysfunction of unknown pathophysiology.
Figure 2 illustrates these results. Note that all the re-
sults in the AD category are very homogeneous: The
first psychiatric symptoms always occur late in life, and the
delay between the first psychiatric symptoms and cognitive
decline is always short. The relationship seems more het-
erogeneous in the two other categories. These observations
could suggest that there is a close link between the two.
However, further, larger studies are needed to confirm these
observations.
In our results, clinical diagnosis and CSF biomarker
results were concordant in about two-thirds of cases,
a finding close to those of neuropathological studies
[10, 11]. Unlike post-mortem histological studies that
reclassify the diagnosis after several years of evolution,
a reclassification based on CSF biomarkers occurred quite
often at the beginning of follow-up and may have thera-
peutic consequences. The distinction between AD and
psychiatric disorders is essential because (1) the prognosis
and management of the patient are different, (2) psychi-
atric symptoms in AD can be the expression of unmet
clinical needs requiring specific treatment while avoiding
antipsychotic drugs and (3) some treatments are not rec-
ommended in neurodegenerative diseases but are widely
used in psychiatric disorders, such as anticholinergic drugs
[37–39]. It clearly appears really helpful to get a precise
differentiation between AD and pure psychiatric disorders
to give and adapt an appropriate treatment and to avoid
deleterious therapeutics and management. Consequently,
for the benefit of the patient and the patient’s family, the
use of biomarkers improves the precision of the diagnosis
and allows provision of better information and medical
care to the patient as well as more specific supportive care
for the patient’s relatives.
Some limitations of the present study have to be con-
sidered. First, there were two aspects of recruiting bias:
(1) The participation of the memory clinics was on a vol-
untary basis, leading to overrepresentation of the clinics
performing LP in routine clinical practice and in clinical
research; and (2) patients were referred for cognitive disor-
ders or atypical psychiatric disorders, probably explaining
the high rate of patients with AD. A similar study in psy-
chiatric centres might produce different results according
to the age and clinical characteristics of the patients as
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well as differences in diagnostic procedures used in psy-
chiatric consultations. In memory centres, clinicians have
to be careful before concluding a diagnosis of psychiatric
disorder and referring patients to a psychiatric centre.
A second limitation is that, because of refusal or medical
contraindications, LP could not be performed in all pa-
tients from the referring centres. Third, even though
previous studies indicated a good correlation between
CSF results and neuropathology [13, 19–21], in this
study we did not have pathological analysis available to
confirm CSF findings. Further assessments using amyloid
and tau PET imaging would certainly be worth trying.
Fourth, psychiatric evaluations were not done using stan-
dardized interviews that would have allowed us to take into
account atypical features and age at onset of the psychiatric
disorders. Fifth, complementary data were recorded retro-
spectively in a subgroup of patients allowing to obtain fol-
low up information but disadvantage to provide blinded
(from CSF biomarker results) information.
Conclusions
As the management and the prognosis of patients with
psychiatric disorders and AD are really different, the re-
sults of the present study are very useful in underlining
the importance of and need for complementary explora-
tions when psychiatric disorders with cognitive decline are
addressed in memory centres. Furthermore, the improve-
ment of AD diagnosis will be important in the future
when appropriate effective therapies become available and
are routinely proposed to patients with AD.
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